Kesimpta® for Relapsing Multiple Sclerosis: Uses, Dosing, and Safety

What Kesimpta® Is and How It Works

Kesimpta® (ofatumumab) is a subcutaneous injection used in adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It targets CD20-positive B cells, which play a role in MS inflammation. By depleting these B cells, it helps reduce relapses and new MRI lesions over time. Many people also search for Kesimpta cost when comparing treatment options in the US.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing. We offer brand and generic medicines at Canadian prices and ship to the US with careful handling.

Kesimpta is supplied as a single-dose prefilled Sensoready autoinjector pen or prefilled syringe. It is taken monthly after a short starter phase. This schedule allows at-home administration instead of infusion visits. Learn more about the condition on our Multiple Sclerosis page.

Dosage and Usage

• Starter and maintenance dosing: 20 mg subcutaneously at Weeks 0, 1, and 2; then 20 mg every 4 weeks starting at Week 4.
• Indication: adults with relapsing MS (CIS, RRMS, active SPMS). Not studied in primary progressive MS.
• Before the first dose: hepatitis B screening and vaccination review are standard; follow your prescriber’s plan.
• Injection sites: abdomen or thigh; outer upper arm if given by a caregiver. Rotate sites.
• Missed dose: administer the missed dose as soon as possible. Take the next dose 4 weeks later from the date the missed dose is given.
• Preparing the pen/syringe: remove from the refrigerator and let it reach room temperature for about 15–30 minutes. Do not warm with heat.
• Check the medicine: the solution should be clear to slightly yellow without particles. Do not use if cloudy or leaking.
• Clean and inject: wash hands, clean the skin with alcohol, remove the cap, pinch the skin, and inject straight in. For the pen, press firmly until it clicks and the indicator shows completion; hold in place for 10–15 seconds.
• After injection: apply light pressure with gauze if needed. Do not rub the site.
• Disposal: place used devices in an FDA-cleared sharps container; do not throw loose needles or pens in household trash.

• Refrigerated storage: store at 2–8 °C (36–46 °F) in the original carton. Protect from light. Do not freeze or shake.
• Room-temperature window: if needed, keep a single pen or syringe at up to 25–30 °C (77–86 °F) for up to 7 days. Do not return it to the refrigerator.
• Travel: keep your Kesimpta with gel packs in an insulated bag. Do not place it directly on ice.
• Before use: allow the device to warm to room temperature out of direct sunlight. Do not use external heat sources.
• Shipping: your order ships with prompt, express, cold-chain handling to maintain temperature control.

Benefits and Savings

Kesimpta helps reduce annualized relapse rates, MRI lesion activity, and the risk of confirmed disability worsening in relapsing MS. Monthly at-home injections avoid infusion appointments, which many patients find more convenient. The Sensoready pen is designed for straightforward use after training.

Novartis Kesimpta has a well-established mechanism (anti-CD20) similar to infusion-based therapies, but with the flexibility of self-injection. Regular monthly dosing supports consistent B-cell suppression and sustained disease control.

Canadian pharmacy pricing can offer meaningful savings. Many shoppers compare Kesimpta price points across pharmacies to manage ongoing therapy costs. Typical savings at YouDrugstore versus usual US prices range about 60–80%, subject to market changes. Multi-month supplies and periodic bulk promotions may further lower the Kesimpta cost per month compared with single-carton purchases. We can send friendly reorder reminders so you do not run out.

We partner with licensed, vetted international pharmacies to source authentic brand medicines, offering a wide selection at affordable prices.

For current deals, see our kesimpta coupon page.

Side Effects and Safety

• Upper respiratory tract infection, sore throat, or runny nose
• Urinary tract infection
• Headache
• Fever or fatigue
• Injection-site reactions (redness, pain, swelling, itching)
• Back pain
• Rash

Serious risks include infections, decreased immunoglobulins, and hepatitis B reactivation. Rare but serious brain infection (progressive multifocal leukoencephalopathy) has been reported with anti-CD20 therapies. Hypersensitivity reactions can occur. Vaccinations should be reviewed before treatment; live vaccines are generally avoided during and for a time after therapy. Discuss pregnancy planning and breastfeeding with your prescriber.

Onset Time

CD20 B-cell depletion starts quickly after the first injections. Many patients see fewer new or enlarging MRI lesions within the first 4–8 weeks. Relapse reduction becomes clearer over several months as maintenance dosing continues. Disability outcomes typically require longer observation, often 6–12 months, to judge trend and stability.

Compare With Alternatives

Ocrelizumab (Ocrevus) is another anti-CD20 therapy given by intravenous infusion twice per year after the starter doses. It offers similar efficacy with clinic-based infusions and periodic monitoring. People who prefer not to self-inject may consider this approach.

Natalizumab (Tysabri) is a monthly infusion that can be highly effective but carries a well-known risk of PML, especially in patients with positive JC virus antibodies. It requires strict monitoring protocols and infusion-center access.

Copaxone® (glatiramer acetate) is a non-immunosuppressive injectable that is administered frequently (daily or three times weekly, depending on strength). It may suit those seeking a longer safety record, though relapse and MRI outcomes differ from anti-CD20 agents.

Combination Therapy

• Usually used as monotherapy to limit additive immunosuppression.
• Short courses of corticosteroids may be used for acute relapses.
• Coordinate vaccine timing before starting therapy when possible; avoid live vaccines during treatment.
• Use caution with other immunosuppressants or cytotoxic agents due to infection risk.
• Symptom treatments (for spasticity, pain, fatigue, bladder issues) can be added as needed under clinician guidance.

Patient Suitability and Cost-Saving Tips

Kesimpta is intended for adults with relapsing forms of MS. It is not for primary progressive MS. It may be unsuitable in people with active infections, current hepatitis B infection, severe immunodeficiency, or a history of life-threatening hypersensitivity to ofatumumab.

Prescribers often review hepatitis B status, immunizations, and immunoglobulin levels before and during therapy. They also consider pregnancy plans and breastfeeding. People with chronic infection risk, frequent serious infections, or markedly low immunoglobulins may need alternative options.

To manage the price of Kesimpta over the long term, many customers compare Kesimpta cost per month and Kesimpta cost per year across pharmacies. Canadian pricing can be lower than typical US pharmacy prices. Ordering more than one carton per shipment and watching for bulk promotions can reduce the per-month spend. Reorder reminders help you stay on schedule without overstocking.

If you are evaluating the cost of Kesimpta relative to employer plans or Medicare co-pays, Canadian mail-order pricing can provide a clear benchmark. We provide transparent Kesimpta price quotes before checkout so you can plan refills.

Authoritative Sources

Novartis Kesimpta patient and product information

Health Canada Drug Product Database

FDA Drugs@FDA listing for ofatumumab (Kesimpta)

Order Kesimpta® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This content is for educational purposes only and does not replace advice from your healthcare professional.